Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521)

Market Cap	27.14B
Revenue (ttm)	9.35B
Net Income (ttm)	1.14B
Shares Out	1.45B
EPS (ttm)	0.78
PE Ratio	24.02
Forward PE	16.58
Dividend	0.20 (1.07%)
Ex-Dividend Date	Jul 10, 2024

Volume	15,401,896
Open	18.52
Previous Close	18.73
Day's Range	18.10 - 18.79
52-Week Range	10.71 - 21.55
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Zhejiang Huahai Pharmaceutical

Zhejiang Huahai Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as high-density polyethylene bottles and polypropylene caps for pharmaceuticals. In addition, the company offers contract manufacturing and other services, as well as import and export trade services. The company was founded in 1989 and is headquartered in Linhai, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 8,221
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600521

Financial Performance

In 2023, Zhejiang Huahai Pharmaceutical's revenue was 8.31 billion, an increase of 0.52% compared to the previous year's 8.27 billion. Earnings were 830.47 million, a decrease of -28.88%.